Finance

Lists
Why is GUTS down ९.६३%?
Dive Deeper
GUTS:NASDAQ
Fractyl Health Inc
US$ ०.८१
-९.६३%
(-०.०८६) 1D
US$ ०.८३
+१.८९% (+०.०१५)
After hours
Closed: नोभेम्बर १०, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GUTS...
Open
US$ ०.८९
High
US$ ०.९०
Low
US$ ०.८१
Mkt. cap
१.०७ करोड
Avg. vol.
८.६० लाख
Volume
३.६८ लाख
52-wk high
US$ २९.३४
52-wk low
US$ ०.८१
EPS
-US$ १३.४३
Shares outstanding
१.३३ करोड
No. of employees
१००
Open
US$ ०.८९
High
US$ ०.९०
Low
US$ ०.८१
Mkt. cap
१.०७ करोड
Avg. vol.
८.६० लाख
Volume
३.६८ लाख
52-wk high
US$ २९.३४
52-wk low
US$ ०.८१
EPS
-US$ १३.४३
Shares outstanding
१.३३ करोड
No. of employees
१००
News stories
From web sources and news partners
Profile
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
About Fractyl Health Inc
CEO-
Employees१००
Founded२०१०
HeadquartersBurlington, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 5 analysts giving stock ratings to GUTS in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for GUTS in the last 3 months.
Highest
Current US$ ०.८१
US$ ३९.०० (+४,७१०.६६%)
Average
US$ १६.०० (+१,८७३.६०%)
Lowest
US$ ४.०० (+३९३.४०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
US$ ३९.००
+४,७१०.७%
10/23/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
US$ ८.००
+८८६.८%
10/22/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
US$ ५.००
+५१६.८%
10/19/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
US$ ४.००
+३९३.४%
10/19/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
US$ २४.००
+२,८६०.४%
10/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.७५ करोड
१.६५ करोड
१.५६ करोड
१.३८ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५२.३७ लाख
६७.९१ लाख
५२.२२ लाख
५२.८४ लाख
Operating expense
२.२७ करोड
२.३३ करोड
२.०८ करोड
१.९१ करोड
Total operating expenses
२.२७ करोड
२.३३ करोड
२.०८ करोड
१.९१ करोड
Operating income
-२.२७ करोड
-२.३३ करोड
-२.०८ करोड
-१.९१ करोड
Other non operating income
-२.१२ करोड
-२.०२ करोड
३.०१ करोड
-५४.९१ लाख
EBT including unusual items
-४.५६ करोड
-४.३७ करोड
९२.१८ लाख
-२.५५ करोड
EBT excluding unusual items
-४.३७ करोड
-४.२८ करोड
९८.२८ लाख
-२.४२ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-४.५६ करोड
-४.३७ करोड
९२.१८ लाख
-२.५५ करोड
Net profit margin
-
-
-
-
Earnings per share
-८.५२
-०.८४
-१.५३
-१.४१
Interest and investment income
१.६६ लाख
६.४५ लाख
५.९३ लाख
४.३१ लाख
Interest expense
-
-
-
-
Net interest expenses
१.६६ लाख
६.४५ लाख
५.९३ लाख
४.३१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.२४ करोड
-२.३० करोड
-२.०५ करोड
-१.८८ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू